Relata^®

Ruxolitinib

Product Information

Proprietary Name: Relata®
Generic Name: Ruxolitinib
Dosage Form: Tablet
Strengths: 5 mg, 10 mg, 15 mg, 20 mg
Indications: Myelofibrosis, Polycythemia Vera, Graft-versus-Host Disease (GvHD)

Oncology

Ruxolitinib is indicated for the treatment of myelofibrosis, polycythemia vera, graft-versus-host disease (GvHD).